Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer.

Concomitant boost chemoradiotherapy in locally advanced head and neck cancer: treatment tolerance and acute side effects.

Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review.

Concomitant chemoradiotherapy as investigational therapy for locoregionally advanced head and neck cancer.

Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.

Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.

Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck.

Head and neck cancer patients' perceptions of swallowing following chemoradiotherapy.

Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706).

Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer.

Progressive resistance training in head and neck cancer patients during concomitant chemoradiotherapy -- design of the DAHANCA 31 randomized trial.

Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation.

Modified weekly cisplatin-based chemotherapy is acceptable in postoperative concurrent chemoradiotherapy for locally advanced head and neck cancer.

Molecular targeting in combination with platinum-based chemoradiotherapy in head and neck cancer treatment.

Observation Versus Neck Dissection for Residual, PET-Negative Lymphadenopathy After Chemoradiotherapy for Head-and-Neck Cancer.

Concurrent chemoradiotherapy in older adults with squamous cell head & neck cancer: Evidence and management.

Chemoradiotherapy in elderly patients with advanced head and neck cancer under intensive nutritional support.

Change of Swallowing in Patients With Head and Neck Cancer After Concurrent Chemoradiotherapy.

Improving therapeutic ratio in head and neck cancer with adjuvant and cisplatin-based treatments.

Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy.

Carnitine is associated with fatigue following chemoradiotherapy for head and neck cancer.

Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer.

Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer.

T cell abundance in blood predicts acute organ toxicity in chemoradiotherapy for head and neck cancer.

The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy.

Suggest Documents

Concomitant boost chemoradiotherapy in locally advanced head and neck cancer: treatment tolerance and acute side effects.

Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review.

Concomitant chemoradiotherapy as investigational therapy for locoregionally advanced head and neck cancer.

Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.

Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.

Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck.

Head and neck cancer patients' perceptions of swallowing following chemoradiotherapy.

Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706).

Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer.

Progressive resistance training in head and neck cancer patients during concomitant chemoradiotherapy -- design of the DAHANCA 31 randomized trial.

Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation.

Modified weekly cisplatin-based chemotherapy is acceptable in postoperative concurrent chemoradiotherapy for locally advanced head and neck cancer.

Molecular targeting in combination with platinum-based chemoradiotherapy in head and neck cancer treatment.

Observation Versus Neck Dissection for Residual, PET-Negative Lymphadenopathy After Chemoradiotherapy for Head-and-Neck Cancer.

Concurrent chemoradiotherapy in older adults with squamous cell head & neck cancer: Evidence and management.

Chemoradiotherapy in elderly patients with advanced head and neck cancer under intensive nutritional support.

Change of Swallowing in Patients With Head and Neck Cancer After Concurrent Chemoradiotherapy.

Improving therapeutic ratio in head and neck cancer with adjuvant and cisplatin-based treatments.

Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy.

Carnitine is associated with fatigue following chemoradiotherapy for head and neck cancer.

Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer.

Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer.

T cell abundance in blood predicts acute organ toxicity in chemoradiotherapy for head and neck cancer.

The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy.

Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer.

Recommend Documents

Follow Us